LAL

RxSight to Participate in the Wells Fargo Healthcare Conference

Retrieved on: 
화요일, 8월 31, 2021
Interest, GLOBE, IOL, Visual acuity, NASDAQ, Patient, Conference, LAL, Technology, Health insurance

ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference.

Key Points: 
  • ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference.
  • RxSights management is scheduled to present Friday, September 10, 2021, at 12:00pm ET.
  • The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
  • The LAL now features ActivShield technology, a revolutionary UV protection layer built into the lens.

RxSight to Report Second Quarter 2021 Financial Results on September 7, 2021 

Retrieved on: 
화요일, 8월 24, 2021
GLOBE, IOL, Visual acuity, LAL, Technology, Patient, Animal, Telescopic sight

ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021.

Key Points: 
  • ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021.
  • The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
  • The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

RxSight, Inc. Expands Commercial Leadership with Addition of Steve Everly as Vice-President of U.S. Sales

Retrieved on: 
화요일, 8월 17, 2021
Terminology, Adoption, Johnson & Johnson, GLOBE, IOL, Visual acuity, NASDAQ, Abbott Laboratories, Patient, Laboratory, Johnson & Johnson Vision, LAL, Technology, Medicine, Telescopic sight, Pharmaceutical industry

Sales.

Key Points: 
  • Sales.
  • In this new position, Mr. Everly will lead the continued development and expansion of the companys sales organization.
  • Most recently, Mr. Everly served as Johnson & Johnson Visions Area Vice President, Surgical Sales Western U.S., responsible for all aspects of Cataract, Refractive and Ocular Surface product sales.
  • Prior to that Mr. Everly spent nine years in roles of increasing responsibility with Abbott Laboratories ultimately becoming Director, US Refractive Sales and nine years in commercial roles at Advanced Medical Optics, Inc.

RxSight Announces Appointments to its Board of Directors

Retrieved on: 
수요일, 8월 11, 2021
Bausch, Visual acuity, Rutgers University, Medtronic, Company, Patient, MBA, Accounting, Technology, Forward-looking statement, GRACE, Senior, IntraLase, Community Exchange System, Spine, Providence College, Financial system, LAL, Terminology, General manager, Pace University, BS, Nasdaq, Board, University, Leadership, Acquisition, Board of directors, IOL, GLOBE, Bausch & Lomb, Growth, Small Business Saturday, Management

The three appointments, including Robert (Bob) Palmisano, Robert Warner and Julie Andrews, joined directors J. Andy Corley, William J.

Key Points: 
  • The three appointments, including Robert (Bob) Palmisano, Robert Warner and Julie Andrews, joined directors J. Andy Corley, William J.
  • Concurrent with the new appointments, the Company announced the resignations of four long-serving board members Bruce Robertson, Ph.D., Daniel Schwartz, M.D., Christopher Cox, and Rick Wolfen.
  • We are excited to welcome Bob, Robert and Julie to the RxSight Board of Directors as we move forward as a public company focused on improving patient vision after cataract surgery.
  • Their shared values and collective expertise across commercial operations, finance and strategy will play a crucial guiding role in the next phase of growth for RxSight, said J. Andy Corley, Chair of the Board of Directors.